جارٍ التحقق…
تُرجمت تلقائيًا. للجرعات والتحذيرات: راجع النص الأصلي بالإنجليزية. اقرأ بالإنجليزية

Orphesic Tablets_

NAFDAC Reg. No. A4-2181 · Drug

Registered with NAFDAC. Registration activeAs of 6 November 2026 · synced automatically from official sources.
Product
Orphesic Tablets_
رقم NAFDAC
A4-2181
المادة الفعالة
Orphenadrine Citrate; Paracetamol
التركيز
35 mg; 450 mg
الشكل
Tablet
حجم العبوة
10 x 10's (in Alu-PVC blisters)
Manufacturer
Not listed
Applicant (holder)
Laider International W.A Ltd
Approved
30 Jul 2025
الحالة
Active View on NAFDAC ↗
التسجيل ساري حتى
29 Jul 2030
تنبيهات منظمة الصحة العالمية
None found
Community reports
None
Times checked
0

About the medicine: Paracetamol: uses, dosage and brands worldwide

What we found

  • Orphesic Tablets_ is on the NAFDAC register with an active registration (A4-2181). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Orphesic Tablets_

ما تقوله النشرة الرسمية. إذا وصفه لك طبيب، فاتبع الوصفة. وإذا اختلفت نشرة عبوتك، فالأولوية لها.

لمن هو

Orphenadrine citrate extended-release tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions.

كيف يُتناول وكم مرة

Adults Two tablets per day; one in the morning and one in the evening.

Children
  • Safety and effectiveness
  • In pediatric patients have not been established
Talk to a doctor first if
  • Orphenadrine citrate extended-release tablets are contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardio-spasm (mega-esophagus) and myasthenia gravis
  • Orphenadrine citrate tablets are contraindicated in patients who have demonstrated a previous hypersensitivity to the drug
Warnings

Some patients may experience transient episodes of light-headedness, dizziness or syncope. Orphenadrine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; ambulatory patients should therefore be cautioned accordingly.

الآثار الجانبية المحتملة

Adverse reactions of orphenadrine are mainly due to the mild anticholinergic action of orphenadrine, and are usually associated with higher dosage. Dryness of the mouth is usually the first adverse effect to appear. When the daily dose is increased, possible adverse effects include: tachycardia, palpitation, urinary hesitancy or retention, blurred vision, dilatation of pupils, increased ocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, drowsiness, hypersensitivity reactions, pruritus, hallucinations, agitation, tremor, gastric irritation, and rarely urticaria and other dermatoses. Infrequently, an elderly patient may experience some degree of mental confusion. …

Pregnancy and breastfeeding

Pregnancy Pregnancy Category C Animal reproduction studies have not been conducted with orphenadrine. It is also not known whether orphenadrine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Orphenadrine should be given to a pregnant woman only if clearly needed.

If you take too much

Orphenadrine is toxic when overdosed and typically induces anticholinergic effects. In a review of orphenadrine toxicity, the minimum lethal dose was found to be 2 to 3 grams for adults; however, the range of toxicity is variable and unpredictable. Treatment for orphenadrine overdose is evacuation of stomach contents (when necessary), charcoal at repeated doses, intensive monitoring, and appropriate supportive treatment of any emergent anticholinergic effects.

الاعتماد وإساءة الاستخدام

Orphenadrine has been chronically abused for its euphoric effects. The mood elevating effects may occur at therapeutic doses of orphenadrine.

إذا نسيت جرعة

تناولها عندما تتذكر، إلا إذا اقترب موعد الجرعة التالية. عندها تخطَّ الجرعة المنسية. لا تتناول جرعتين معًا أبدًا للتعويض. راجع النشرة، فبعض الأدوية مختلفة.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2026-01-01.

Label for orphenadrine citrate and paracetamol, the active ingredient registered with NAFDAC.

Check your pack of Orphesic Tablets_

Add the expiry date on your pack for a full Trust Score.

أو التقط صورًا للعبوة
تبقّت 3 عمليات تحقق مجانية اليوم Official sources: U.S. FDA · EMA (EU) · Health Canada · WHO alerts

About Orphesic Tablets_

What is in Orphesic Tablets_?

Orphesic Tablets_ contains Orphenadrine Citrate; Paracetamol (35 mg; 450 mg), as tablet, according to its NAFDAC registration record.

Is Orphesic Tablets_ registered with NAFDAC?

Yes. Orphesic Tablets_ is listed on the NAFDAC register under registration number A4-2181, and its registration is active as of 6 November 2026.

Has Orphesic Tablets_ been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Orphesic Tablets_ in our automatically synced alert list.

How can I check that my pack of Orphesic Tablets_ is genuine?

Run a free authenticity scan with the NAFDAC number A4-2181, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Orphesic Tablets_?

Follow your prescription or the leaflet in your pack. The official label says: Adults Two tablets per day; one in the morning and one in the evening.…

What is Orphesic Tablets_ used for?

Orphenadrine citrate extended-release tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. (Summarised from the official U.S. FDA label for orphenadrine citrate and paracetamol. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Orphesic Tablets_? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.